Optimal control for resistance and suboptimal response in CML

Mathematical Biosciences

Volumn 227, Issue 2, 2010, Pages 81-93

  Aïnseba, Bedr'Eddine ^a   Benosman, Chahrazed ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic myeloid leukemia; Control problems; Hematopoiesis; Imatinib therapy; Optimization and variational techniques; Suboptimal response and resistance

Indexed keywords

BLOOD; CYTOLOGY; DISEASE CONTROL; MOLECULAR BIOLOGY; OPTIMAL CONTROL SYSTEMS; STEM CELLS; VARIATIONAL TECHNIQUES;

CHRONIC MYELOID LEUKEMIAS; CONTROL PROBLEMS; DIFFERENTIATED CELLS; HEMATOLOGICAL DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; IMATINIB; OPTIMAL CONTROL PROBLEM;

DISEASES;

IMATINIB;

BLOOD; CANCER; CELL ORGANELLE; DRUG RESISTANCE; FOUR-DIMENSIONAL MODELING; HEMATOLOGY; LITERATURE REVIEW; MATHEMATICAL THEORY; NONLINEARITY; NUMERICAL MODEL; OPTIMIZATION;

CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GROWTH REGULATION; HEALTH CARE COST; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; LEUKEMIA CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONLINEAR SYSTEM; REVIEW; THERAPY EFFECT;

EID: 77956183822     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2010.06.005     Document Type: Review

References (27)

1. Adimy M., Angulo O., Crauste F., López-Marcos J.C. Numerical integration of a mathematical model of hematopoietic stem cell dynamics. Computers and Mathematics with Applications 2008, 56:594.
2. Brezis H. Analyse Fonctionnelle. Théorie et Applications 1999, Dunos, Paris.
3. Catlin S.N., Guttorp P., Abkowitz J.L. The kinetics of clonal dominance in myeloproliferative disorders. Blood 2005, 106:2688.
4. Colijn C., Mackey M.C. A mathematical model of hematopoiesis: periodic chronic myelogenous leukemia, part I. Journal of Theoretical Biology 2005, 237:117.
5. Cotta C.V., Bueso-Ramos C.E. New insights into the pathobiology and treatment of chronic myelogenous leukemia. Annals of Diagnostic Pathology 2007, 11:68.
6. Culshaw R.V., Ruan S., Spiteri R. Optimal HIV treatment by maximising immune response. Journal of Mathematical Biology 2004, 48:545.
7. Deininger M.W.N., OBrien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. Journal of Clinical Oncology 2003, 21:1637.
8. Dingli D., Michor F. Successful therapy must eradicate stem cells. Stem Cells 2006, 24:2603.
9. Fleming W.H., Rishel R.W. Deterministic and Stochastic Optimal Control 1975, Springer-Verlag, New York Heidelberg Berlin.
10. Graham S.M., et al. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319.
11. Hocking L.M. Optimal Control, An Introduction to the Theory with Applications 1991, Clarendon Press, Oxford.
12. Leguay T., Mahon F.-X. Leucémie myéloïde chronique. EMC-Hématologie 2005, 2:187.
13. Mackey M.C. A unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis. Blood 1978, 51:941.
14. Mackey M.C. Mathematical models of hematopoietic cell replication and control. The art of mathematical modelling: case studies in ecology. Physiology and Biofluids 1997, 149. Prentice Hall. H.G. Othmer, F.R. Adler, M.A. Lewis, J.C. Dallon (Eds.).
15. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukemia. Nature 2005, 435:1267.
16. Nanda S., Moore H., Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Mathematical Biosciences 2007, 210:143.
17. Perot C. La résistance à l'imatinib est-elle toujours liée à la présence d'un allèle bcr-abl muté dans la LMC?. Hématologie 2006, 12:225.
18. Pujo-Menjouet L., Mackey M.C. Contribution to the study of periodic chronic myelogenous leukemia. Comptes Rendus Biologies 2004, 327:235.
19. Roche-Lestienne C., Mahon F.-X., Preudhomme C. Origine de la résistance au traitement par imatinib mésylate. Medecine/Sciences 2004, 20:1125.
20. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M., Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medecine 2006, 12:1181.
21. Rousselot P. Critères et traitement des réponses insuffisantes à l'imatinib dans la leucémie myéloïde chronique. Hématologie 2006, 12:19.
22. Scheijen B., Griffin J.D. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002, 21:3314.
23. Schroeder T. Asymmetric cell division in normal and malignant hematopoietic precursor cells. Cell Stem Cell 2007, 1:479.
24. M. Tulliez, Traitement de la leucémie myéloïde chronique en 2007, Nouvelles approches diagnostiques et thérapeutiques en hématologie, 25-29 (2007).
25. Volpe G., Panuzzo C., Ulisciani S., Cilloni D. Imatinib resistance in CML. Cancer Letters 2009, 274:1.
26. N.Widmer, L.A.Décosterd, Imatinib plasma concentrations variability in hemato-oncologic patients, Thèse de doctorat, Faculté de biologie et de médecine de l'Université de Lausanne, 2006.
27. You B., Trillet-Lenoir V. Thérapeutiques anticancéreuses ciblées. La revue de médecine interne 2006, 27:S285.